What You Should Know:
- Helix, a leader in population genomics and precision health, today announced the launch of a new clinico-genomic dataset comprising over 15,000 patients treated with glucagon-like peptide-1 (GLP-1) agonists.
- These medications, which include semaglutide, tirzepatide, and liraglutide, are increasingly used to treat type 2 diabetes, obesity, and other metabolic conditions.
GLP-1 Agonist Virtual Registry
This research-ready dataset, known as a
Read More
Life Sciences | News, Analysis, Insights - HIT Consultant
Vantive Launches as Independent Vital Organ Therapy Company
What You Should Know:
- Vantive, formerly known as Baxter Kidney Care, today announced its launch as a new standalone company focused on vital organ therapies.
- The formation follows the completion of its acquisition by funds managed by Carlyle (NASDAQ: CG) from Baxter International Inc. (NYSE: BAX). Building on a 70-year legacy of innovation in kidney care, Vantive is committed to extending lives and expanding possibilities for patients with kidney disease and other vital
Read More
Cellular Connectivity: The Future of Home Medical Devices
The global home medical equipment market is experiencing explosive growth. Smart devices are being used to monitor and treat patients suffering from diabetes, cardiac disorders, and other medical conditions without exposing those patients to the risk of hospital-acquired infections. Numerous organizations, including the World Health Organization and the National Council of Aging, are promoting self-health management to give patients better outcomes.
This trend leverages digital technology to
Read More
Medidata and Cognizant Expand Partnership to Accelerate Clinical Trial Development
What You Should Know:
- Cognizant (Nasdaq: CTSH) announced an expanded agreement with Medidata, a Dassault Systèmes brand and leader of clinical trial solutions to the life sciences industry, to provide support for Medidata's life sciences clients and expand the strategic alliance partnership.
- Over the years, the companies have partnered to deliver a comprehensive framework supporting life sciences clients, emphasizing customer success, patient service desk, implementation,
Read More
Owkin Doses First Patient in Phase I Trial of AI-Optimized Cancer Therapy OKN4395
What You Should Know:
- Owkin, an AI-powered biotech company, today announced the dosing of the first patient in its Phase I clinical trial of OKN4395, a novel cancer therapy designed to restore immune function in patients with advanced solid tumors.
- OKN4395 represents a novel approach to cancer treatment by targeting multiple immunosuppressive pathways simultaneously.
OKN4395 Background
OKN4395 is a first-in-class asset that selectively inhibits three
Read More
Harnessing AI and LLMs to Accelerate Biomedical Discovery for Precision Medicine
The healthcare industry is experiencing a data and technological revolution that is accelerating drug discovery and delivery to patients. Over the past 15 years, we've seen an explosion of targeted therapies — including small molecules, immunotherapies, cell-based treatments, and more — all made possible by the integration of large-scale 'omics data with clinical insights, treatment approaches, and patient outcomes. However, despite these advancements, we still have a long way to go to fully
Read More
ActiGraph and Hyfe Launch AI-Powered Cough Detection for Clinical Trials
What You Should Know:
- ActiGraph, the global leader in wearable digital health technology for clinical research and drug development, and Hyfe Inc., the pioneer in AI-powered cough detection technology, have announced the release of their new digital health solution for detection of coughs using the ActiGraph LEAP wearable.
- This new combined solution allows researchers to leverage Hyfe’s validated cough detection algorithms alongside ActiGraph’s industry-leading digital measures for
Read More
Amplitude Vascular Systems Secures $36M to Advance Treatment for Calcified Arterial Disease
What You Should Know:
- Amplitude Vascular Systems (AVS), a medical device company focused on safely and effectively treating severely calcified arterial disease with its novel PULSE IVL™ platform, announced today that it has completed a Series B round of financing of $36M.
- The funding will support the U.S. peripheral commercial launch as well as U.S. coronary and carotid IDE trials for the company’s Pulse Intravascular Lithotripsy™ (PIVL™) device.
Amplitude Vascular Systems
Read More
OSE Immunotherapeutics & Scienta Lab Partner to Advance AI-Driven Drug Discovery
What You Should Know:
- OSE Immunotherapeutics SA, a biotechnology company focused on developing innovative immunotherapies, and Scienta Lab, a pioneer in AI-driven precision immunology is forming a strategic collaboration to leverage the power of artificial intelligence (AI) in the fight against inflammatory diseases.
- The partnership will harness Scienta Lab's advanced AI platform, EVA, to identify predictive biomarkers of efficacy for immunotherapies. EVA is a multimodal
Read More
Lantheus to Acquire Evergreen Theragnostics to Expand Radiopharmaceutical Capabilities
What You Should Know:
- Lantheus Holdings, Inc., a radiopharmaceutical company, announced today a definitive agreement to acquire Evergreen Theragnostics, Inc., a clinical-stage radiopharmaceutical company.
- The all-cash transaction consists of an upfront payment of $250M and up to an additional $752.5M in potential milestone payments.
- The acquisition marks Lantheus' fifth deal since January 2024 and solidifies its position as a fully integrated
Read More
